Clinical Trial Update: Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients [NA]

View source ↗

Summary

This document details an ongoing clinical trial evaluating the PET imaging agent [68Ga]DOTA-IR-780-C-4 for PSMA-positive prostate cancer, with enrollment by inv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• [68Ga]DOTA-IR-780-C-4 (68Ga-DOTA-IR-780-C-4 radiotracer for PET imaging)

Snippet

Sponsor: Affiliated Hospital of Jiangnan University | Conditions: PET CT | NA | Status: ENROLLING_BY_INVITATION